Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05280314
Title Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors IO Biotech
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DNK | DEU | AUS

Facility Status City State Zip Country Details
Yale RECRUITING New Haven Connecticut 06519 United States Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Massey Cancer Center RECRUITING Richmond Virginia 23219 United States Details
Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital RECRUITING Sydney New South Wales Sydney 2060 Australia Details
Peter MacCallum Cancer Centre RECRUITING Melbourne Victoria 3VIC 3000 Australia Details
Aarhus University Hospital RECRUITING Aarhus 8200 Aarhus Denmark Details
Copenhagen University Hospital Herlev RECRUITING Copenhagen 9 DK-2730 Denmark Details
CHRU Lille RECRUITING Lille 59037 Lille France Details
Hôpital Ambroise-Paré RECRUITING Paris 92104 Boulogne France Details
Institut Gustave Roussy RECRUITING Paris 94805 Villejuif France Details
Universitätsklinikum Essen & Research Alliance Ruhr RECRUITING Essen D-45147 Essen Germany Details
Universität Heidelberg, Medizinische Fakultät RECRUITING Heidelberg 69120 Heidelberg Germany Details
Hospital Universitario Quirón Dexeus RECRUITING Barcelona 08028 Barcelona Spain Details
Hospital Universitario Ramón y Cajal RECRUITING Madrid Madrid 28034 Spain Details
Hospital Clínico Universitario de Valencia -INCLIVA RECRUITING Valencia 46010 Valencia Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field